Page 53 - Read Online
P. 53

Page 243                                                            Huang et al. J Transl Genet Genom 2021;5:240-9  https://dx.doi.org/10.20517/jtgg.2021.14

               Table 1. Summary of studies about the association between HSD3B1 variants and PCa treated with ADT
                Study          Medical management  No. of Cases  No. of Carriers  Results                       Conclusions
                Ross et al. [15] , 2008*  ADT    529            62              For TTP:                        The polymorphism in HSD3B1 was associated with time to
                                                                                HR = 0.58; 95%CI: 0.41-0.81; P = 0.0047  progression during ADT for PCa
                     [16]
                Wu et al.  , 2015  ADT           103            18              For incidence of CRPC:          Variant HSD3B1 associated higher incidence of CRPC
                                                                                AC vs. AA: 100% vs. 64.7%; P = 0.003
                       [17]
                Hearn et al.  , 2016  ADT        118            74              For PFS:                        Patients carrying variant HSD3B1 are more likely to fail
                                                                                CC: HR = 2.4; 95%CI: 1.1-5.3; P = 0.029   with ADT and to have worse survival outcome
                                                                                AC: HR = 1.7; 95%CI: 1.0-2.9; P = 0.041
                                                                                For OS:
                                                                                CC: HR = 3.3; 95%CI: 1.3-8.3; P = 0.013
                                                                                AC: HR = 2.0; 95%CI: 1.1-3.7; P = 0.036
                               ADT               137            60              For PFS:
                                                                                CC: HR = 2.7; 95%CI: 1.2-5.9; P = 0.013
                                                                                AC: HR = 1.0; 95%CI: 0.7-1.7; P = 0.085
                               ADT               188            90              For OS:
                                                                                CC: HR = 2.5; 95%CI: 1.2-5.0; P = 0.013
                                                                                AC: HR = 1.5; 95%CI: 1.0-2.1; P = 0.036
                Agarwal et al. [18] , 2017  ADT  102            52              For PFS:                        HSD3B1 genotype CC but not AC, was associated with
                                                                                CC: HR = 2.16; 95%CI: 1.01-4.58; P = 0.046   shorter PFS
                                                                                AC: HR = 1.04; 95%CI: 0.64-1.07; P = 0.86
                       [20]
                Hearn et al.  , 2018  ADT after radiotherapy  218  116          For time to metastasis:         Variant HSD3B1 was associated with shorter time to
                                                                                CC: HR = 2.01; 95%CI: 1.02-3.97; P = 0.045   metastasis but not with death and progression risk
                                                                                AC: HR = 1.19; 95%CI: 0.74-1.92; P = 0.48
                                                                                No significant differences in TTP or OS
                       [19]
                Shiota et al.  , 2019  ADT       104            9               For PFS:                        Variant HSD3B1 was associated with shorter PFS but not
                                                                                CC/AC: HR = 2.34; 95%CI: 1.08-4.49; P = 0.03   with death risk
                                                                                For OS:
                                                                                CC/AC: HR = 1.36; 95%CI: 0.52-2.92; P = 0.50
                       [21]
                Hearn et al.  , 2020  ADT randomized plus   475  270            For PFS:                        Variant HAD3B1 was associated with higher risk of
                               docetaxel                                        In low-volume disease group:    progression and death for patients with low-volume
                                                                                CC/AC: HR = 1.89; 95%CI: 1.13-3.14; P = 0.02   disease, but not with high-volume
                                                                                In high-volume disease group:
                                                                                CC/AC: HR = 1.10; 95%CI: 0.82-1.47; P = 0.52
                                                                                For OS:
                                                                                In low-volume disease group:
                                                                                CC/AC: HR = 1.74; 95%CI: 1.01-3.00; P = 0.045
                                                                                In high-volume disease group:
                                                                                CC/AC: HR = 0.89; 95%CI: 0.65-1.22; P = 0.48
                      [23]
                Chen et al.  , 2020  ADT         101            42              For OS:                         Variant HSD3B1 was marginally significantly associated
                                                                                CC/AC vs. AA: 5.0 years vs. 6.5 years; P = 0.052 with shorter OS
               *Except for the study by Ross et al. [15]  (rs1856888), all other studies investigated the variant rs1047303. ADT: Androgen deprivation therapy; TTP: time to progression; HR: hazard ratio; 95%CI: 95% confidence
               interval; CRPC: castrate-resistant prostate cancer; PFS: progression-free survival; OS: overall survival.
   48   49   50   51   52   53   54   55   56   57   58